Celldex Therapeutics
CLDX
157 hedge funds and large institutions have $1.28B invested in Celldex Therapeutics in 2022 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 49 increasing their positions, 50 reducing their positions, and 27 closing their positions.
125% more call options, than puts
Call options by funds: $141M | Put options by funds: $62.7M
2% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 50
3.07% less ownership
Funds ownership: 105.65% → 102.57% (-3.1%)
7% less funds holding
Funds holding: 168 → 157 (-11)
22% less capital invested
Capital invested by funds: $1.65B → $1.28B (-$367M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
30% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$26.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$15.9M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$14.3M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$11M |
| 5 |
CC
Commodore Capital
New York
|
+$8.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$20M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$17.5M |
| 3 |
Morgan Stanley
New York
|
-$15.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$15.1M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$14.9M |
CLDX Hedge Fund Activity: Q2 2022 in Review
157 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q2 2022, worth a combined $1.28B — down 22% from $1.65B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of CLDX and 19 opened new positions — a net loss of 8 holders — while 50 trimmed existing stakes and 49 added.
The largest buyer was Bellevue Group, opening a new position worth an estimated $26.9M. The largest seller was Wellington Management Group, cutting an estimated $20M.
- 157 institutional investors held Celldex Therapeutics (CLDX) as of Q2 2022, down from 168 in Q1 2022.
- Funds reported $1.28B of Celldex Therapeutics stock for Q2 2022, down 22% quarter-over-quarter.
- 19 funds opened new Celldex Therapeutics positions in Q2 2022 and 27 closed out, a net change of -8 holders.
- The largest Celldex Therapeutics buyer in Q2 2022 was Bellevue Group, an estimated $26.9M added.
- The largest Celldex Therapeutics seller in Q2 2022 was Wellington Management Group, an estimated $20M sold.
Based on aggregated 13F filings for Q2 2022.